Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m² with advanced ovarian cancer.

IF 4.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

International Journal of Gynecological Cancer Pub Date : 2025-08-22 DOI:10.1016/j.ijgc.2025.102122

Matthew Savas, Erin Bailey, Erik Harrington, Eleni Gamvroulas, T Joseph Mattingly, Theresa L Werner

{"title":"Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m2 with advanced ovarian cancer.","authors":"Matthew Savas, Erin Bailey, Erik Harrington, Eleni Gamvroulas, T Joseph Mattingly, Theresa L Werner","doi":"10.1016/j.ijgc.2025.102122","DOIUrl":null,"url":null,"abstract":"Objective: We sought to describe the treatment tolerability of carboplatin when dosed based on actual versus adjusted body weight in patients with a body mass index (BMI) ≥25 kg/m2 who had advanced ovarian cancer.Methods: In this single-center, retrospective, descriptive analysis, we included patients with advanced-stage epithelial ovarian cancer who had a BMI ≥25 kg/m2 and received first-line treatment with carboplatin and paclitaxel. We compared patients who received carboplatin dosed based on actual body weight with those whose dosing was based on adjusted body weight. The primary endpoint was the composite incidence of treatment modifications.Results: A total of 101 patients were included in this study: 61 in the actual body weight-based dosing group and 40 in the adjusted body weight-based dosing group. There was no significant difference in the incidence of treatment modifications between groups (73.8% vs 57.5%, p = .09). Dose reductions of carboplatin and treatment delays were more common in the actual body weight-based dosing group (39.3% vs 15.0%, p = .009) and (32.8 vs 5.0%, p = .001), respectively. Grade ≥3 neutropenia (19.7% vs 12.5%) and thrombocytopenia (13.1% vs 0.0%) were higher in the actual body weight group. More patients in the adjusted body weight-based dosing group initiated next-line therapy (55% vs 26.2%, p = .004). Median time to next treatment or death was not reached in the actual body weight-based dosing group but was 19.3 months (95% CI 12.4 to 24.0) in the adjusted body weight-based dosing group (HR 0.32, 95% CI 0.18 to 0.58, p = .0001). Death from any cause was lower in the actual body weight group (19.7% vs 60.0%, HR 0.35, 95% CI 0.18 to 0.71, p = .003).Conclusions: Dosing carboplatin using adjusted body weight in patients with a BMI ≥25 kg/m2 may lead to fewer carboplatin dose reductions and treatment delays.","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102122"},"PeriodicalIF":4.7000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2025.102122","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We sought to describe the treatment tolerability of carboplatin when dosed based on actual versus adjusted body weight in patients with a body mass index (BMI) ≥25 kg/m² who had advanced ovarian cancer.

Methods: In this single-center, retrospective, descriptive analysis, we included patients with advanced-stage epithelial ovarian cancer who had a BMI ≥25 kg/m² and received first-line treatment with carboplatin and paclitaxel. We compared patients who received carboplatin dosed based on actual body weight with those whose dosing was based on adjusted body weight. The primary endpoint was the composite incidence of treatment modifications.

Results: A total of 101 patients were included in this study: 61 in the actual body weight-based dosing group and 40 in the adjusted body weight-based dosing group. There was no significant difference in the incidence of treatment modifications between groups (73.8% vs 57.5%, p = .09). Dose reductions of carboplatin and treatment delays were more common in the actual body weight-based dosing group (39.3% vs 15.0%, p = .009) and (32.8 vs 5.0%, p = .001), respectively. Grade ≥3 neutropenia (19.7% vs 12.5%) and thrombocytopenia (13.1% vs 0.0%) were higher in the actual body weight group. More patients in the adjusted body weight-based dosing group initiated next-line therapy (55% vs 26.2%, p = .004). Median time to next treatment or death was not reached in the actual body weight-based dosing group but was 19.3 months (95% CI 12.4 to 24.0) in the adjusted body weight-based dosing group (HR 0.32, 95% CI 0.18 to 0.58, p = .0001). Death from any cause was lower in the actual body weight group (19.7% vs 60.0%, HR 0.35, 95% CI 0.18 to 0.71, p = .003).

Conclusions: Dosing carboplatin using adjusted body weight in patients with a BMI ≥25 kg/m² may lead to fewer carboplatin dose reductions and treatment delays.

查看原文本刊更多论文

在体重指数≥25kg /m2的晚期卵巢癌患者中，治疗耐受性与基于实际体重和调整体重的卡铂剂量相关。

目的：我们试图描述在体重指数(BMI)≥25 kg/m2的晚期卵巢癌患者中，根据实际体重与调整体重给药时卡铂的治疗耐受性。方法：在这项单中心、回顾性、描述性分析中，我们纳入了BMI≥25 kg/m2并接受卡铂和紫杉醇一线治疗的晚期上皮性卵巢癌患者。我们比较了根据实际体重给药的卡铂的患者和根据调整体重给药的卡铂的患者。主要终点是治疗改变的综合发生率。结果：本研究共纳入101例患者：实际体重给药组61例，调整体重给药组40例。两组间治疗修改的发生率无显著差异（73.8% vs 57.5%, p = 0.09）。卡铂的剂量减少和治疗延迟在以体重为基础的给药组中更为常见（分别为39.3% vs 15.0%, p = 0.009）和（32.8 vs 5.0%, p = 0.001）。≥3级中性粒细胞减少症（19.7% vs 12.5%）和血小板减少症（13.1% vs 0.0%）在实际体重组较高。调整体重给药组中更多的患者开始了下一步治疗（55% vs 26.2%, p = 0.004）。以实际体重为基础给药组未达到下一次治疗或死亡的中位时间，但以调整体重为基础给药组为19.3个月（95% CI 12.4至24.0）（HR 0.32, 95% CI 0.18至0.58,p = 0.0001）。实际体重组任何原因的死亡率较低（19.7% vs 60.0%, HR 0.35, 95% CI 0.18 ~ 0.71, p = 0.003）。结论：BMI≥25kg /m2的患者使用调整体重的卡铂可能导致较少的卡铂剂量减少和治疗延迟。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Gynecological Cancer 医学-妇产科学

CiteScore

6.60

自引率

10.40%

发文量

280

审稿时长

3-6 weeks

期刊介绍： The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.